Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

351
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
351
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

5.4K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
5.4K
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

3.1K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
3.1K
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

4.4K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
4.4K
Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

8.9K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
8.9K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

2.6K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Pharmacokinetics of Cannabinoids Delivered by Diverse Routes in Rodents.

Medical cannabis and cannabinoids·2026
Same author

Evaluation of Deflection Prediction Models for RC Beams with High-Strength Steel Reinforcement.

Materials (Basel, Switzerland)·2026
Same author

Are Cannabis and/or Cannabinoids a Potential Therapy for ALS?

Muscle & nerve·2026
Same author

Cannabichromene attenuates fracture pain but impairs bone repair in a murine tibial fracture model.

Bone·2026
Same author

Cirrhosis of the liver adversely affects the clinical outcomes in patients with acute pancreatitis: A propensity-matched nationwide analysis (2016-2020).

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]·2026
Same author

Use of rituximab for fulminant and refractory cases of immune checkpoint inhibitor induced myocyte injury clinically presenting with features of myasthenia gravis: a case series.

European heart journal. Case reports·2025

Related Experiment Video

Updated: Aug 9, 2025

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies
05:25

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies

Published on: December 29, 2021

2.6K

CANNabinoid Drug Interaction Review (CANN-DIR™).

Paul T Kocis1,2, Samuel Wadrose3, Ryan Lee Wakefield3

  • 1Department of Pharmacy, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA.

Medical Cannabis and Cannabinoids
|February 23, 2023
PubMed
Summary
This summary is machine-generated.

A new tool, CANN-DIR™, screens for drug interactions between medical cannabis (THC, CBD) and other medications. This free platform helps patients and providers understand potential risks and facilitates informed discussions.

Keywords:
CANN-DIRCannabidolCannabinoidDelta-9-THC; ∆9-THCDrug-drug interactionMedication reconciliationReviewTetrahydrocannabinolURL

More Related Videos

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
07:51

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice

Published on: August 1, 2025

44
Development of a Preclinical Inhalation Model to Test Vaporized Cannabis Distillates
06:09

Development of a Preclinical Inhalation Model to Test Vaporized Cannabis Distillates

Published on: May 30, 2025

243

Related Experiment Videos

Last Updated: Aug 9, 2025

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies
05:25

Tobacco Hornworm as an Insect Model System for Cannabinoid Pre-clinical Studies

Published on: December 29, 2021

2.6K
Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice
07:51

Administration of Δ9-Tetrahydrocannabinol (THC) in Adolescent and Adult Mice

Published on: August 1, 2025

44
Development of a Preclinical Inhalation Model to Test Vaporized Cannabis Distillates
06:09

Development of a Preclinical Inhalation Model to Test Vaporized Cannabis Distillates

Published on: May 30, 2025

243

Area of Science:

  • Pharmacology
  • Drug Interactions
  • Cannabinoid Therapeutics

Background:

  • Non-prescription cannabidiol (CBD) and medical marijuana lack FDA-approved prescribing information for drug interactions.
  • Existing resources do not adequately address potential interactions between cannabinoids and other medications.

Purpose of the Study:

  • To develop and introduce the CANNabinoid Drug Interaction Review (CANN-DIR™) platform.
  • To provide a free, web-based resource for screening cannabinoid-drug interactions.

Main Methods:

  • CANN-DIR™ screens interactions based on FDA-approved prescribing information for prescription cannabinoids and medications with shared metabolic enzymes.
  • Data sources include FDA prescribing information and the "Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers".
  • Information for nabiximols (Sativex®) was sourced from its Summary of Product Characteristics (SmPC).

Main Results:

  • CANN-DIR™ offers an expedited review of potential drug-drug interactions involving THC, CBD, or THC/CBD combinations.
  • The platform allows patients and healthcare providers to print search results for discussion and documentation.
  • Search results and navigation are available in ten languages to reach a global audience.

Conclusions:

  • CANN-DIR™ provides a valuable, accessible tool for evaluating cannabinoid-drug interactions.
  • The platform supports informed decision-making for patients and healthcare providers.
  • Multilingual support enhances global accessibility and utility for understanding cannabinoid medication safety.